Curated News
By: NewsRamp Editorial Staff
September 15, 2026
Instinct Bio Receives Nasdaq Notices for Listing Deficiencies
TLDR
- Instinct Bio has 180 days to lift its share price above one dollar and market values above required thresholds or face delisting.
- Nasdaq notified Instinct Bio of three listing deficiencies concerning market value, publicly held shares, and minimum bid price.
- Instinct Bio's efforts to maintain its Nasdaq listing support its regenerative medicine work and long-term therapeutic development for patients.
- Instinct Bio must keep its shares above one dollar and market values above fifty million dollars for ten straight days to regain compliance.
Impact - Why it Matters
This news matters because it highlights the financial and regulatory pressures facing Instinct Bio, a biotechnology company focused on regenerative medicine. Failure to regain compliance with Nasdaq's listing standards could result in delisting, which would significantly impact the company's access to capital and investor confidence. For shareholders, delisting could mean reduced liquidity and potential losses. The broader biotech industry also watches such cases as indicators of market conditions and the challenges smaller companies face in maintaining public listings. How Instinct Bio navigates this period will be crucial for its future growth and stability.
Summary
Instinct Bio Technical Company Holdings Inc. (Nasdaq: BIOT, BIOTW) is facing significant challenges to its continued listing on The Nasdaq Global Market. The biotechnology company, focused on regenerative medicine and therapeutic platforms, announced on September 15, 2026, that it received three separate notifications from Nasdaq's Listing Qualifications Department on September 9 and 10, 2026. These notifications cite deficiencies in the Market Value of Listed Securities (MVLS), Market Value of Publicly Held Shares (MVPHS), and minimum bid price requirements. The MVLS fell below the required US$50 million, the MVPHS dropped below US$15 million, and the bid price remained under US$1.00 per share. While these notifications do not immediately affect trading, Instinct Bio has been granted 180-day compliance periods, ending in early March 2027, to regain compliance. If the company fails to do so, it may face delisting, though it can appeal or consider transferring to The Nasdaq Capital Market.
The company is evaluating options to address these deficiencies, but there is no guarantee of success. This news comes as a critical test for Instinct Bio, which must now navigate regulatory hurdles to maintain its Nasdaq listing. Investors and stakeholders will be watching closely as the company works to meet the necessary requirements within the given timeframe. For more details, view the original release on www.newmediawire.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Instinct Bio Receives Nasdaq Notices for Listing Deficiencies
